Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

ClinicalTrials.gov ID: NCT06751238

Public ClinicalTrials.gov record NCT06751238. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA

Study identification

NCT ID: NCT06751238
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 20 participants

Conditions and interventions

Conditions

Juvenile Psoriatic Arthritis

Interventions

Secukinumab Biological

Biological

Eligibility (public fields only)

Age range: 2 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 24, 2025 (Actual)
Primary completion: Oct 31, 2029 (Estimated)
Completion: Mar 11, 2031 (Estimated)
Last update posted: Oct 13, 2026

2025 – 2031

United States locations

U.S. sites: 11
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
Loma Linda University Health	Loma Linda	California	92354	Recruiting
University of Florida	Gainesville	Florida	32610-8068	Recruiting
Ann and Robert H Lurie Childs Hosp	Chicago	Illinois	60611	Recruiting
Col Uni Med Center New York Presby	New York	New York	10032	Recruiting
Levine Childrens Hospital	Charlotte	North Carolina	28203	Recruiting
Cincinnati Childrens Hospital	Cincinnati	Ohio	45229	Recruiting
Univ Hosp Cleveland Medical Center	Cleveland	Ohio	44106-5028	Recruiting
Legacy Emanuel Research Hosp Portland	Portland	Oregon	97232	Recruiting
Childrens Hosp Pittsburgh UPMC	Pittsburgh	Pennsylvania	15224	Recruiting
Texas Arthritis Center	El Paso	Texas	79902	Recruiting
University of Utah	Salt Lake City	Utah	84113	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06751238, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 13, 2026 · Synced Oct 29, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06751238 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →